Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA)

NCT01550003 is registered in ClinicalTrials.gov with UCB BIOSCIENCES GmbH as lead sponsor.

NCT NCT01550003
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01550003 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
Lead sponsor
UCB BIOSCIENCES GmbH
Phase
Phase 3
Overall status
Completed
Start date
March 8, 2012
Completion date
April 8, 2024
Enrollment
193 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

polyarticular-course juvenile idiopathic arthritis (jia)